We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+14.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$949M
AUM Growth
+$37.8M
Cap. Flow
-$30.5M
Cap. Flow %
-3.21%
Top 10 Hldgs %
31.29%
Holding
98
New
10
Increased
21
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$34M
2
ZBH icon
Zimmer Biomet
ZBH
+$18.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.6M
4
ISRG icon
Intuitive Surgical
ISRG
+$10.3M
5
PRCT icon
Procept Biorobotics
PRCT
+$9.22M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$21.9M
2
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$8.61M
3
THC icon
Tenet Healthcare
THC
+$8.54M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$8.33M
5
UNH icon
UnitedHealth
UNH
+$7.82M

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Industrials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
26
DELISTED
Exact Sciences
EXAS
$16.4M 1.73%
175,000
+85,000
+94% +$6.63M
SWAV
27
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$16M 1.68%
56,000
-11,000
-16% -$3.05M
ISRG icon
28
Intuitive Surgical
ISRG
$134B
$15M 1.59%
44,000
+34,000
+340% +$10.3M
DHR icon
29
Danaher
DHR
$144B
$14.4M 1.52%
67,680
+16,920
+33% +$3.58M
IMGN
30
DELISTED
Immunogen Inc
IMGN
$14.2M 1.49%
750,000
-500,000
-40% -$5.9M
PRVA icon
31
Privia Health
PRVA
$2.87B
$12M 1.27%
460,000
+64,333
+16% +$1.7M
AXNX
32
DELISTED
Axonics, Inc. Common Stock
AXNX
$11.6M 1.22%
230,000
-41,062
-15% -$2.18M
ALKS icon
33
Alkermes
ALKS
$8.25B
$11M 1.15%
350,000
+215,000
+159% +$6.51M
IQV icon
34
IQVIA
IQV
$39.3B
$10.6M 1.11%
47,000
+26,000
+124% +$5.22M
PRCT icon
35
Procept Biorobotics
PRCT
$1.17B
$9.86M 1.04%
+279,000
New +$9.22M
NTRA icon
36
Natera
NTRA
$46.4B
$9.73M 1.03%
200,000
-17,000
-8% -$867K
DVAX
37
DELISTED
Dynavax Technologies
DVAX
$9.04M 0.95%
700,000
-25,000
-3% -$285K
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$29.3B
$8.55M 0.9%
45,000
-31,000
-41% -$6.15M
LNTH icon
39
Lantheus
LNTH
$6.59B
$8.39M 0.88%
+100,000
New +$8.97M
TXG icon
40
10x Genomics
TXG
$6.61B
$7.59M 0.8%
136,000
-14,000
-9% -$758K
KRTX
41
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$7.59M 0.8%
35,000
-2,000
-5% -$428K
BNTX icon
42
BioNTech
BNTX
$23.5B
$7.56M 0.8%
70,000
-22,000
-24% -$2.47M
HRMY icon
43
Harmony Biosciences
HRMY
$2.24B
$7.39M 0.78%
210,000
+40,000
+24% +$1.38M
OM icon
44
Outset Medical
OM
$90.8M
$7.23M 0.76%
22,042
-15,291
-41% -$4.66M
VEEV icon
45
Veeva Systems
VEEV
$37.4B
$6.92M 0.73%
35,000
-2,000
-5% -$365K
GKOS icon
46
Glaukos
GKOS
$10.6B
$6.76M 0.71%
95,000
+3,000
+3% +$172K
MOH icon
47
Molina Healthcare
MOH
$10.3B
$6.54M 0.69%
+21,700
New +$6.24M
CYTK icon
48
Cytokinetics
CYTK
$10.4B
$6.52M 0.69%
200,000
-5,000
-2% -$185K
ITCI
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.02M 0.63%
95,000
-10,000
-10% -$623K
IOVA icon
50
Iovance Biotherapeutics
IOVA
$2.87B
$5.98M 0.63%
850,000
+163,830
+24% +$1.17M
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Rhenman & Partners Asset Management held 98 positions worth $949M, up 4.1% from $911M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $30.5M in Q2 2023, closing 15 positions and reducing 41 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $8.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Eli Lilly worth $38M.

  • Rhenman & Partners Asset Management's largest Q2 2023 buy was Eli Lilly: 81,000 shares worth $38M.
  • Rhenman & Partners Asset Management added most to BioMarin Pharmaceuticals in Q2 2023, an estimated $14.6M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2023 reduction was Thermo Fisher Scientific, cutting an estimated $21.9M.
  • Rhenman & Partners Asset Management fully exited Silk Road Medical, Inc. Common Stock in Q2 2023, selling an estimated $8.61M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $949M portfolio in Q2 2023.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 15 in Q2 2023.
  • Rhenman & Partners Asset Management's portfolio value rose 4.1% quarter-over-quarter to $949M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.